Measuring And Monitoring Turnaround Time For TB Test Results
Timely tuberculosis (TB) test results help clinicians begin appropriate treatment, support infection prevention, and improve notification of people who may have been exposed. For laboratories, turnaround time (TAT) is also a practical indicator of how well the testing pathway functions from specimen receipt to result communication.
A useful TAT monitoring system must do more than produce an average number of hours or days. It should show where delays occur, whether urgent samples receive appropriate priority, and whether performance is consistent across test methods, facilities, shifts, and reporting channels.
The measurement process should fit the laboratory’s quality management system and available resources. A small facility may begin with a paper log and a monthly review, while a larger network may use a laboratory information system with automated timestamps and dashboards. In both settings, clear definitions and disciplined recording are essential.
Define The Testing Clock Clearly
Before collecting data, the laboratory should define the start and end points for each TAT indicator. A common laboratory TAT begins when a correctly labeled specimen is received and accepted, then ends when the validated result is released to the authorized requester. This measures laboratory performance without confusing it with transport time or clinical decision-making.
Other intervals may be equally important. Total pathway time can run from specimen collection to result receipt at the testing facility or from collection to delivery of the result to the clinician. Separating these intervals helps distinguish delays caused by transportation, accessioning, testing, result validation, referral, or communication.
The definition should also state whether weekends, public holidays, instrument downtime, rejected specimens, repeat testing, and referral testing are included. Calendar time is usually easiest for clinical interpretation, while working time may better reflect staff and equipment performance. The chosen method matters less than applying it consistently and reporting it transparently.
Map The Process And Set A Baseline
Start by mapping the complete workflow for each major TB diagnostic service, such as smear microscopy, molecular testing, culture, drug susceptibility testing, or line probe testing. Identify every handoff and timestamp: collection, dispatch, receipt, registration, test start, result review, release, and communication. The map often reveals that the longest delay occurs before or after the analytical test.
The GLI Quality Tool’s quality management guidance can help laboratories connect TAT monitoring with documented processes, responsibilities, assessment, and continual improvement. This prevents TAT from becoming an isolated indicator owned only by the bench staff.
Establish a baseline using several weeks or months of routine data rather than a few unusually good or poor days. Include enough results to show normal variation, and stratify the baseline by test type, specimen source, referring site, priority status, and testing location. Record the number of tests alongside the time values so that a small sample does not distort the apparent performance.
Capture Reliable And Useful Data
Each TAT record needs a unique specimen or patient identifier, while protecting confidentiality. At minimum, capture specimen collection date and time, laboratory receipt, accessioning, testing, result authorization, and result dispatch or electronic release. The record should also identify the assay, testing site, specimen category, and any interruption or exception.
If the laboratory cannot record every stage immediately, begin with the timestamps that are most feasible and most influential. For example, receipt-to-result-release TAT may be a realistic first indicator. The system can later add transport and communication intervals as staff become familiar with the process.
Use consistent rules for incomplete records. A missing timestamp should be reported as missing data rather than silently replaced with an estimate. Supervisors should review impossible sequences, such as a result released before specimen receipt, and investigate duplicate entries, clock differences, and manual transcription errors. The phase checklists provide a practical way to review whether documentation and monitoring activities are being implemented as intended.
| Measurement | What it shows | Best use | Common limitation |
|---|---|---|---|
| Median TAT | The typical result time for the middle observation | Routine monthly monitoring | Can hide very long delays |
| 90th percentile TAT | The time within which 90% of results are completed | Service-level and patient-impact review | Needs a reasonable number of results |
| Mean TAT | Overall arithmetic average | Comparing stable, similar datasets | Distorted by extreme delays |
| Percentage within target | Proportion completed by an agreed deadline | Performance accountability | Depends on a realistic target |
| Range or maximum | Spread and worst observed delay | Finding exceptional failures | Highly sensitive to single events |
| Stage-specific TAT | Time spent in transport, testing, validation, or reporting | Locating bottlenecks | Requires several reliable timestamps |
Analyze Variation Rather Than Averages Alone
The median is often a useful summary for routine TB testing because a few extreme delays can make the mean appear worse than the experience of most patients. The 90th percentile adds a view of reliability by showing the time within which nearly all results are completed. Laboratories should report both when the dataset is large enough.
A performance dashboard can include the number of specimens received, median TAT, 90th percentile, percentage released within target, rejected specimens, repeat tests, and missing timestamps. Displaying results by week or month makes gradual deterioration visible. Run charts are especially useful because they show shifts, trends, and unusual points without requiring complex statistical software.
Analysis should be stratified before conclusions are made. A combined result may look acceptable even when a rural referral site, night shift, or high-priority test pathway performs poorly. Compare routine and urgent samples, different instruments, staff shifts, facilities, and specimen types. Review delays in relation to stock-outs, power interruptions, calibration, transport schedules, maintenance, workload, and referral arrangements.
Set Targets That Reflect Clinical Need
A TAT target should be clinically meaningful, operationally realistic, and agreed with laboratory and clinical stakeholders. It may differ by service: rapid molecular testing, culture confirmation, and drug susceptibility testing have different analytical requirements and workflow constraints. A single target for every TB test can encourage misleading comparisons.
Targets should be expressed in a way staff can apply. For example, a laboratory might define a target for the percentage of eligible specimens with results released within a specified number of working hours, while separately monitoring total calendar time from collection to result receipt. The target should identify the starting event, ending event, test category, and exclusions.
Use baseline findings to set an initial target, then tighten it as avoidable delays are reduced. Targets should never encourage rushed verification, skipped quality checks, or release of unreliable results. Analytical quality, biosafety, documentation, and authorization remain essential parts of a timely service.
Investigate Delays And Improve The Workflow
When performance falls below target, review individual delayed specimens and group them by cause. A simple cause classification might include late transport, incomplete request forms, accessioning backlog, reagent shortage, instrument failure, repeat testing, delayed review, communication failure, or incomplete data entry. The objective is to identify system causes rather than assign blame to individuals.
Corrective actions should have an owner, a due date, and a measure of effectiveness. Examples include revising courier schedules, introducing a specimen acceptance checklist, creating a daily pending-results review, maintaining critical reagent stocks, or establishing an escalation process for instrument downtime. After implementation, compare subsequent TAT with the baseline and check whether another stage has become the new bottleneck.
The user instructions explain how to work with the resource’s phases and materials, which can support a structured review of procedures, responsibilities, records, and improvement actions. Laboratories can align TAT work with relevant Quality Systems Essentials, including organization, personnel, equipment, purchasing and inventory, documents and records, assessment, and continual improvement.
Make Monitoring A Routine Management Practice
Assign responsibility for data review at each level. Bench staff may record events, a quality officer may check completeness and produce the monthly analysis, and the laboratory manager may review trends and authorize corrective actions. Clinical and transport partners should receive relevant findings when delays occur outside the testing room.
A short, regular review is more effective than an annual analysis that arrives after problems have become established. Discuss the dashboard during quality meetings, document decisions, and track open actions until they are closed. Include staff feedback because people performing the workflow often know why timestamps are missed or why specimens wait.
Practical actions for a sustainable TAT system include:
- Define separate start and end points for collection-to-result, receipt-to-result, and result communication intervals.
- Record timestamps at every feasible handoff and audit a sample of entries for accuracy each month.
- Report median TAT, a high-percentile measure, and the percentage completed within target.
- Stratify results by assay, facility, priority, shift, and referral pathway before interpreting performance.
- Link every recurring delay to a documented corrective action and follow-up measurement.
A laboratory that measures TAT consistently can show whether service changes are producing real benefits for people with presumptive TB. Begin with a clearly defined indicator, establish a trustworthy baseline, and use routine review to remove delays without compromising result validity. Apply the GLI Quality Tool resources to organize the work, engage the full testing network, and turn each TAT review into a practical step toward a stronger quality management system.